BRAF and melanoma: In this study, we utilized the Flatiron Health database to retrospectively assess brain metastasis free survival (BMFS) from time of initiation of 1L therapy (immunotherapy, or targeted therapies) to metastasis or death in patients with advanced BRAF mutant melanoma.